 
THESE DOCUMENTS ARE THE PROPERTY OF BOSTON SCIENTIFIC CORP. AND SHALL NOT BE REPRODUCED, 
DISTRIBUTED, DISCLOSED OR USED FOR MANUFACTURE OR SALE OF APPARATUS WITHOUT THE EXPRESS WRITTEN 
CONSENT OF BOSTON SCIENTIFIC CORP.  
20-Oct-[ADDRESS_376785] Protocol  
90914721 /Ver AD 
  Page [ADDRESS_376786]  
 
 
 
CLINICAL PROTOCOL  
 
E7059  
Current Version: Octo ber 20, [ADDRESS_376787] Protocol  
CDM00047339 /Ver AD 
  Page [ADDRESS_376788] Protoc ol  
90914721 /Ver AD 
  Page 3 of 44 
  
Do not copy or distribute without written permission.  
Investigatorâ€™s Signature [CONTACT_168882]:  Randomized Multi -Center Study Comparing No Drainage to 
Preoperative Biliary Drainage Using Metal Stents in Patients 
with Resectable Pancreatic or Periampullary Cancer  
STUDY CENTER:  _____________________________________________  
(Print name [CONTACT_205425])  
 
PROTOCOL VERSION : AD 
 
 
We, the undersigned, have read and understand the protocol specified above and agree on its 
content.  We agree to perform and conduct the study as described in the protocol.  In 
addition, when applicable, we agree to enlist sub-investigators who also agree to perform and 
conduct the study as described in the protocol.  
 
 
 
 
 
Principal Investigator  
[INVESTIGATOR_278443]:    
 
 
 
Date  
 
 
 
 
 
Co-Principal  Investigator (if applicable)  
Print name:    
 
 
 
[CONTACT_307984]  
20-Oct-[ADDRESS_376789] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376790]  
Objective(s)  To demonstrate that preoperative biliary drainage using self -expanding 
metal stents (SEMS) does not negatively impact overall surgical 
outcomes in patients undergoing pancreaticoduodenectomy for treatment 
of pancreatic or periampullary  cancer . 
Test Device  Devices : 
WallFlex Biliary RX Fully Covered  stent   
Note: WallFlex Biliary RX Uncovered stent s may be used in some 
cases as outlined in the protocol  
Cleared Indication s:  
The WallFlex Biliary stents are indicated for use in the palliative 
treatment of biliary strictures produ ced by [CONTACT_307961]: T he WallFlex Biliary FC stent is also indicated for the 
treatme nt of benign biliary strictures  per CE Mark  or other local 
regulations  
Study Design  â€¢ Prospective , multi-center , randomized , post -market (on label)   
â€¢ Patients will be block randomized at baseline in a 1:1 ratio between  
Group 1: No Pre -Operative Biliary Drainage and Group 2: Pre-
Operative Biliary Drainage with a SEMS.    
Planned 
Number of 
Subjects  294 total number of subjects:  
â€¢ Group 1: 147 
â€¢ Group 2: [ADDRESS_376791] Protoc ol  
90914721 /Ver AD 
  Page 5 of 44 
 Secondary 
Endpoints  1. Adverse events: r ate, severity , seriousness , relatedness  to stent or 
endoscopic or surgical procedure , impact on time of surgery, 
length of hospi[INVESTIGATOR_307947]   
2. Time to surgery  
3. Curative Intent Surgery details  pertaining to intraoperative 
assessment of resectability, surgical resection and reconstruction 
techniques   
4. Intraoperative blood loss and blood transfusions, duration of 
surgery  
5. Biliary  obstructive symptoms assessment (Week 2, 
surgery/transition to palli ation, [ADDRESS_376792] -operative follow up 
and 120 day follow up)  
6. Improvement of LFT levels as relative to baseline  (Week 2, 
surgery/transition to palliation, [ADDRESS_376793] -operative follow up 
and 120 day follow up)  
7. Stent placement success: ability  to deploy the stent in satisfactory 
position across the stricture (Group 2)  
8. Stent removal success:  successful SEMS removal, either  en bloc  
at time of surgery or endoscopi[INVESTIGATOR_307948]    
9. Number, type, reason and timing  of biliary re -interventions  
10. Number and duration of h ospi[INVESTIGATOR_307949] s  
Follow -up 
Schedule  and 
Assessment s â€¢ Screening : Count  all consecutive patients seen at investigational site 
presenting with biliary obstructive symptoms and suspi[INVESTIGATOR_307950], distal common bile duct cholangiocarcinoma or 
peri-ampullary  cancer . Of those, a subset will be invited to participate 
in trial: Informed Consent  (enrollment) and Eligibility Criteria 
Assessment   
â€¢ Baseline Visit  (Day 0) : Demographics, Medical History, Tumor 
Diagnosis, Staging  and Characteristics,  Assessment of Biliary 
Obstructive Symptoms, Laboratory Tests , Randomization  
â€¢ Stent Placement  Procedure Visit (Group 2  only, Day 0):   Stent 
Details , Procedure Details,  Adverse Events  (AEs)  
â€¢ Pre-Operative Visit  (Week 2 ):  Assessment of Biliary Obstructive 
Symptoms, Laboratory Tests , AEs  
Group 1 ( No Pre -Operative Biliary Drainage ): Patients will undergo  
resection per institutional standard of practice.  Time to surgery is not 
to exceed [ADDRESS_376794] Protoc ol  
90914721 /Ver AD 
  Page 6 of 44 
 physiologic status, or other factors that preclude surgery.  
Group 2  (Pre-Operative Biliary Drainage with a SEMS ):  Patients 
will undergo resection after resolution o f jaundice is achieved 
(defined as Bilirubin below 100 ï­mol per liter), or at [ADDRESS_376795].   
â€¢ Biliary Reintervention Visit (as needed):   Timing, Reason  for 
Biliary Reintervention , Type of Biliary Reintervention ,  AEs 
Group 1 patients who fail their treatment algorithm by [CONTACT_307962] a study SEMS.  
Group 2 patients who require re -stenting or placement of a stent for a 
new stricture, will receive a study SEMS.  
â€¢ Curative Intent  Surgery: Assessment of Biliary Obstructive 
Symptoms, Laboratory Tests , Operative  Details , Stent Removal, 
Blood Loss,  Intra - and Post -Operative  Transfusion, Post -Operative 
Course, Specimen Pathology, AE s 
â€¢ Transition to Palliative Management Visit (as needed) : 
Assessment of Biliary Obstructive Symptoms, Laboratory Tests , AEs 
â€¢ Post-Operative Follow up  Visit ([ADDRESS_376796]-Surgery , if 
applicable) : Assessment of Biliary Obstructive Symptoms, 
Laboratory Tests , AEs 
â€¢ Long Term Follow -up Visit ([ADDRESS_376797] 
randomization):   Assessment of Biliary Obstructive Symptoms, 
Laboratory Tests , AEs   
Patients who undergo  surgery as planned  will be evaluated at [ADDRESS_376798] -randomization.  
Patients with a delay in planned surgery  whose rescheduled surgery is 
unable to occur within 120 days will be followed up to 120 days after 
randomization.  
Patients who do not undergo surgery  as planned due to conversio n to 
palliative management or patient choice will be followed up to 120 
days after randomization.   If patientâ€™s course of treatment requires 
placement of a biliary stent, stenting will be done per standard of care 
at each institution.  If a metal stent is required, a study WallFlex 
Biliary FC stent will be placed.    
Key Inclusion 1. Age [ADDRESS_376799] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376800]  
(CBD)  cholangiocarcinoma and other periampullary cancers 
(histology not required)  
4. Biliary obstructive symptoms or signs  
5. Bilirubin level at/above 100 Î¼mol per liter  (5.8 mg/dL)  
6. Distal biliary obstruction consistent  with pancreatic  cancer , distal 
CBD cholangiocarcinoma or other  periampullary  malignancy  
7. Location of distal biliary obstruction is such that it would allow 
the proximal end of a stent to be positioned at least  [ADDRESS_376801] anatomy, not including prior 
cholecystectomy  
4. Neoadjuvant chemotherapy  for current malignancy  
5. Palliative indication due to reasons other than surgical candidate 
status  
6. Previous  biliary drainage by [CONTACT_307963]/PTC  
7. Patients for whom  endoscopic techniques are contraindicated  
8. Participation in another investigational trial within 90 days  
9. Pregnancy   
Primary 
Statistical 
Hypothesis  A literature search of preoperative biliary drainage with self -expanding 
metal stents in patients with pancreatic or periampullary cancer yielded 
eight articles with 305 patients.1-8 
A meta -analysis of the probability for pre -operative, operative and peri -
operative complications was performed.    A rate of 24.2% [95% CI: 13.2%, 
                                                                                                               Confidential  
20-Oct-[ADDRESS_376802] Protoc ol  
90914721 /Ver AD 
  Page 8 of 44 
 37.2%] was calculated using th e eight  articles.  
Statistical testing will be performed to determine if the  rate of complications 
for the Pre-Operative Biliary Drainage with SEMS  group is non -inferior 
to the No Pre -Operative Biliary Drainage  group.  The null hypothesis is 
that the complication rate is inferior in the Pre-Operative Biliary Drainage 
with SEMS  versus the No Pre -Operative Biliary Drainage  group : 
ğ»ğ‘œ: ğœ‹ğ‘¡ğ‘’ğ‘ ğ‘¡âˆ’ğœ‹ğ‘ğ‘œğ‘›ğ‘¡ğ‘Ÿğ‘œğ‘™  â‰¥âˆ†  (Inferior)  
 
ğ»ğ‘: ğœ‹ğ‘¡ğ‘’ğ‘ ğ‘¡âˆ’ğœ‹ğ‘ğ‘œğ‘›ğ‘¡ğ‘Ÿğ‘œğ‘™  <âˆ†  (Non -inferior)  
 
where ğœ‹ğ‘¡ğ‘’ğ‘ ğ‘¡  and ğœ‹ğ‘ğ‘œğ‘›ğ‘¡ğ‘Ÿğ‘œğ‘™ are the probabilities of having pre-operative, 
operative and peri -operative complications in the Pre-Operative Biliary 
Drainage with SEMS  arm and No Pre -Operative Biliary Drainage  arm 
respectively, and âˆ† is defined as the non -inferiority margin.  
 
The s ample size was calculated for a one -sided 0.[ADDRESS_376803] 9Â® . If the P value from the exact Farrington -
Manning test is <0.05 then the Pre-Operative Biliary Drainage with 
SEMS  group will be considered non -inferior to the No Pre -Operative 
Biliary Drainage  group. The expected  probability of complications in the  
Pre-Oper ative Biliary Drainage with SEMS  arm and No Pre -Operative 
Biliary Drainage  arm is 37.2%, which was taken from the upper limit of 
the 95% CI from the meta -analysis described above and from the only 
available Level 1 study comparing no drainage to preoperati ve stenting in 
which the complication rate was reported to be 39% in the no drainage 
arm.9 The non -inferiority margin ( âˆ†) is 15%.  Given these assumptions 
and a one -sided 5% significance level, 2 x 132 = 264 subjects will 
provide 80 % power to reject the nu ll hypothesis , that the Pre-Operative 
Biliary Drainage with SEMS  group is inferior to the No Pre -Operative 
Biliary Drainage  group.  
To compensate for possible loss of subjects after enrollment and complete 
assessment of inclusion/exclusion criteria, an add itional 10% of subjects 
will be enrolled, for a total of 2 x 147 = [ADDRESS_376804] Protoc ol  
90914721 /Ver AD 
  Page 9 of 44 
 TABLE OF CONTENTS  
1. INTRODUCTION  ................................ ................................ ................................ .................  12 
1.1. Pancreatic and Periampullary cancer  ................................ ................................ .. 12 
1.2. Treatment of Pancreatic/Periampullary Cancer ................................ .................  12 
1.3. Biliary Drainage in Patients with Pancreatic/Periampullary Cancer  ...............  [ADDRESS_376805] SELECTION  ................................ ................................ ................................ .........  16 
5.1. Study Population and Eligibility  ................................ ................................ ...........  16 
5.2. Inclusion Criteria  ................................ ................................ ................................ ... 16 
5.3. Exclusion Criteria  ................................ ................................ ................................ .. 17 
6. STUDY DEVICES  ................................ ................................ ................................ ................  17 
7. STUDY VISITS  ................................ ................................ ................................ ....................  19 
7.1. Visit S chedule  ................................ ................................ ................................ .........  19 
7.2. Screening  ................................ ................................ ................................ .................  21 
7.3. Baseline Visit (Day 0) â€”Office Visit ................................ ................................ ...... 21 
7.4. Stent Placement Procedure Visit (Group 2 subjects only) â€”Office Visit (may 
occur during Baseline visit)  ................................ ................................ ...................  21 
7.5. Pre-Operative Visit (Week 2  +/-  3 days )â€”Telephone or Office Visit  ..............  22 
7.6. Biliary Reintervention Visit (Group 1 or 2) â€”as needed  ................................ ... 22 
7.7. Curative Intent Surgery â€”Office Visit (within [ADDRESS_376806] -randomization)  ................................ ................................ ...............  22 
7.8. Transition to Palliative Management Visit (if applicable) â€”Telephone or 
Office Visit  ................................ ................................ ................................ ..............  [ADDRESS_376807] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376808]-Operative Follow -up Visit ([ADDRESS_376809] -Surgery +/ - 7 days, if 
applicable) â€”Telephone or Office Visit  ................................ ................................  23 
7.10.  Long Term Follow -up Visit (120 days â€”[ADDRESS_376810] randomization +/ - 14 
days) â€”Telephone or Office Visit  ................................ ................................ ..........  [ADDRESS_376811]-Procedure Endpoints  ................................ ................................ ..........  26 
8.4.3.  Subgroup Analyses  ................................ ................................ ....................  26 
8.4.4.  Justification of Pooling  ................................ ................................ ..............  26 
8.4.5.  Multivariable Analyses  ................................ ................................ ..............  27 
8.4.6.  Changes to Planned Analyses  ................................ ................................ .... 27 
9. POTENTIAL RISKS AND BENEFITS  ................................ ................................ ....................  27 
9.1. Anticipated Adverse Device Effects with Use of WallFlex Biliary Stent  ..........  27 
9.2. Anticipated Adverse Events in Patients Without Pre -Operative Biliary 
Drainage  ................................ ................................ ................................ ..................  28 
9.3. Anticipated Surgical Adverse Events  ................................ ................................ ... 28 
9.4. Risk Minimization Actions  ................................ ................................ ....................  29 
9.5. Anticipated Benefits  ................................ ................................ ...............................  29 
9.6. Risk to Benefit Rationale  ................................ ................................ .......................  29 
10. SAFETY REPORTING  ................................ ................................ ................................ ..........  29 
10.1.  Definitions and Classification  ................................ ................................ ...............  29 
10.2.  Relationship to Study Device(s)  ................................ ................................ ............  [ADDRESS_376812] Protoc ol  
90914721 /Ver AD 
  Page 11 of 44 
 10.4.  [LOCATION_011] Scientific Device Deficiencies  ................................ ................................ .... 32 
10.5.  Reporting to Regulatory Authorities / IRBs / ECs / Investigators  ....................  33 
11. BIBLIOGRAPHY  ................................ ................................ ................................ ..................  33 
12. APPENDICES :  SPONSOR REQUIRED PROTOCOL SECTIONS  ................................ .............  35 
12.1.  Data Management  ................................ ................................ ................................ .. 35 
12.1.1 . Data Collection, Processing, and Review  ................................ ..................  35 
12.1.2.  Data Retention  ................................ ................................ ...........................  36 
12.2.  Amendments  ................................ ................................ ................................ ...........  36 
12.3.  Deviations  ................................ ................................ ................................ ................  36 
12.4.  Device/Equipment Accountability  ................................ ................................ ........  [ADDRESS_376813]/ Ethics Committee  ................................ ...................  39 
12.7.  Sponsor Responsibilities  ................................ ................................ ........................  39 
12.8.  Insurance  ................................ ................................ ................................ .................  40 
12.9.  Monitoring  ................................ ................................ ................................ ..............  40 
12.10.  Informed Consent  ................................ ................................ ....................  40 
12.11.  Committees  ................................ ................................ ...............................  41 
12.11.1.  Safety Monitoring Process  ................................ ................................ .........  41 
12.12.  Suspension or Termination  ................................ ................................ ..... 42 
12.12.1.  Premature Termination of the Study  ................................ ..........................  42 
12.12.2.  Criteria for Premature Termination of the Study  ................................ ....... 42 
12.12.3.  Termination of Study Particip ation by [CONTACT_71636]/ EC Approval  ................................ ................................ .....................  [ADDRESS_376814] Follow -up ........................  42 
12.12.5.  Criteria for Suspending/Terminating a Study Center  ................................  43 
12.13.  Publication Policy  ................................ ................................ ....................  43 
12.14.  Definitions of complication criteria (per van der Gaag article):  .........  [ADDRESS_376815] Protoc ol  
90914721 /Ver AD 
  Page 12 of 44 
 1. Introduction  
1.1. Pancreatic and Periampullary cancer  
Pancreatic cancer is the fourth leading cause of cancer death in the US and worldwide  with 
217,000 new cases/year and 213,000 deaths worldwide .10, 11    Relative 1 -year and 5 -year 
survival rates are 26% and 6% respectively.[ADDRESS_376816] .18  Endoscopic ultrasound (EUS) can be used complementary to CT  to 
provide add itional vascular invasion information or to evaluate periampullary masses .19, 20 
Although histologic diagnosis is not necessary before surgical treatment, a biopsy can be 
taken using fine -needle aspi[INVESTIGATOR_307951] -guidance (preferred) or CT -guidanc e.18    
Diagnostic staging laparoscopy is also utilized, and is mostly valuable when there is a need to 
rule out sub -radiologic metastases (especially for body and tail lesions) .21, 22  
Based on results from imaging studies described above, p atients with pancrea tic cancer can 
be divided into four  prognostic subgroups  (Stages I-IV) to allow for choi ce of proper 
treatment course .  These groups are based on local tumor resectability status and presence or 
absence of distant disease  as defined by [CONTACT_307964] r-node -metastasis (TNM) staging system of 
the American Joint Commission on Cancer (AJCC) .23 Patients in whom the primary tumor 
can be removed are classified as localized  resectable ( Stages I and II ), and patients whose 
tumors are unresectable are classifie d as locally advanced (Stage  III) and metastatic (Stage 
IV).24 
Criteria for resectability vary but usually include the absence of distant metastases and no 
tumor inv olvement of major arteries; in cases of venous invasion  of the tumor , there must be 
a suitable segment of portal vein (above) and superior mesenteric vein (below) the site of 
venous involvement to allow for venous reconstruction .25  
1.2. Treatment of Pancreatic /Periampullary  Cancer  
The only potential curative treatment option for patients with resectable 
pancreatic/periampullary cancers is curative -intent -surgery (CIS) by 
[CONTACT_307965] (Whipple procedure)26 with a long -term survival rate of 20% and a 
median survival of 12 -20 months.24 Only 15 -20% of patients presenting with pancreatic 
cancer have potentially resectable tumors.[ADDRESS_376817] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376818] cells24 and 
accounting for over 90% of pancreatic m alignancies .12 
1.3. Biliary Drainage in Patients with Pancreatic /Periampullary  Cancer  
Biliary obstruction associated with  pancreatic/periampullary cancer occurs in up to 70% of 
patients .[ADDRESS_376819] been shown to be superior to plastic stents for 
preoperative biliary drainage in pancreatic cancer1 because of longer patency achieved by a 
greater stent diameter ,31 fewer ERCP procedures, and fewer epi[INVESTIGATOR_307952] s/cholestasis due to stent occlusion while awaiting surgery (15% using SEMS vs 
93% using  plastic stents ).[ADDRESS_376820] -market  (on label) , prospective, multi -center, randomized, non -blinded study.   
Patients will be followed for [ADDRESS_376821] -surgery follow up visit.  
There will be up to 20 participating centers world -wide with anticipated enrollment of 294 
patients, 147 per group.    
At each investigational center, there will be one principal investigator (PI) and at least one 
Co-PI.  At a minimum, there will be one gastroenterologic endoscopi[INVESTIGATOR_307953].  Al though more than two investigators 
per center are allowed, it is encouraged that the number be kept small.  
  
                                                                                                               Confidential  
20-Oct-[ADDRESS_376822] Protoc ol  
90914721 /Ver AD 
  Page 14 of 44 
 3.2. Treatment Assignment  
Patients will be randomized at baseline in equal proportions of 1:1 ratio between Group 1 and 
Group 2 as follows:  
â€¢ Group 1 : No pre-operative biliary drainage (patients will not receive a stent)  
â€¢ Group 2 : Pre-operative biliary drainage with a SEMS  
Block randomization through an online database system will be used.  Randomization will be 
stratified by [CONTACT_91294].  
Figure [ADDRESS_376823] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376824] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376825]  
4.2. Secondary Endpoints  
1. Adverse events: rate, severity, seriousness, relatedness  to stent or endoscopic or 
surgical procedure, impact on time of surgery, length of hospi[INVESTIGATOR_307947]  
2. Time to surgery  
3. Curative Intent Surgery details  pertaining to intraoperative assessme nt of 
resectability, surgical resection and reconstruction techniques   
4. Intraoperative blood loss and blood transfusions, duration of surgery  
5. Biliary  obstructive symptoms assessment (Week 2, surgery/transition to palliation, [ADDRESS_376826] -operative follow up  and 120 day follow up)  
6. Improvement of LFT levels as relative to baseline  (Week 2, surgery/transition to 
palliation, [ADDRESS_376827] -operative follow up and 120 day follow up)  
7. Stent placement success: ability  to deploy the stent in satisfactory position across  the 
stricture (Group 2)  
8. Stent removal success:  successful SEMS removal, either  en bloc  at time of surgery or 
endoscopi[INVESTIGATOR_307954]    
9. Number, type, reason and timing of biliary re -interventions  
10. Number and duration of hospi[INVESTIGATOR_307955]  
5. Subject Selection  
5.1. Study Population and Eligibility  
All consecutive patients seen at an investigational site presenting with biliary obstructive 
symptoms with suspi[INVESTIGATOR_307956] , periampullary  cancer  or distal CBD 
cholangiocarcinoma  will be counted . Of those, a subset will be invited to participate in trial  
and is considered enrolled after signing the study specific Informed Consent Form (ICF) . A 
screening log will be maintained  to document the assessment of eligibility criteria provided 
in Section 5.2  and Section 5.3 . 
5.2. Inclusion Criteria  
Subjects  who meet all of the criteria  listed below may be given consideration for inclusion in 
this clinical investigation, provided no exclusion criterion  (see Section  5.3) is met . 
                                                                                                               Confidential  
20-Oct-[ADDRESS_376828] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376829] (CBD) 
cholangiocarcinoma and other periampullary cancers (histology not required)  
4. Biliary obstructive symptoms  or signs  
5. Bilirubin level at/above 100 ï­mol per l iter (5.8 mg/dL)  
6. Distal biliary obstruction consistent with pancreatic cancer , distal CBD 
cholangiocarcinoma or other  periampullary  malignancy  
7. Location of distal biliary obstruction is such that it would allow the proximal end of a 
stent to be positioned at least  2cm from the hilum  
8. Patients deemed as resectable by [CONTACT_307966]   
9. Surgical candidate per pancreatobiliary surgeon after multi -disciplinary discussion  
10. Surgery intent within [ADDRESS_376830] anatomy , not including prior cholec ystectomy   
4. Neoadjuvant chemotherapy  for current malignancy  
5. Palliative indication due to reasons other than surgical candidate status  
6. Previous  biliary drainage by [CONTACT_307963]/PTC  
7. Patients for whom endoscopic techniques are contraindicated  
8. Participation in another investigational trial within [ADDRESS_376831] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376832] 
confluence, or other anatomic considerations to be specified.     
The WallFlex Biliary RX Fully Co vered and the WallFlex Biliary RX Uncovered Stent 
Systems are indicated for use in the palliative treatment of biliary strictures produced by 
[CONTACT_307967] ; the 
WallFlex Biliary RX Fully Covered Stent System is also indicated for treatment of benign 
biliary strictures, per CE Mark  or other local regulations . For a detailed description of the 
WallFlex Biliary Stent Systems, please reference the Directions for Use ( DFU) included in 
each device package.  
Investigators should use the WallFlex Biliary RX Fully Covered and Uncovered Stent 
Systems in accordance with the DFUs.  
Study devices are labeled on the box and inner pouch and contain information including but 
not li mited to:  device name [CONTACT_5759], lot number, expi[INVESTIGATOR_320], name [CONTACT_282090], and investigational use statement. Device labeling will be provided in local 
language(s) as per national regulations.  
Study devices will be available in the fol lowing dimensions:  
 
WallFlex Biliary 
RX Stent  Diameter  Length  Delivery 
System 
Diameter  Guidewire 
Diameter  
 Uncovered  8 mm  
10 mm  40, 60 , 80 
40, 60 , 80 8 Fr .035â€  
Fully Covered  8 mm  
10 mm  60, 80mm 
40, 60 , 80mm 8.5 Fr  .035â€  
 
Stent placement should be such that the proximal end of the stent is minimum [ADDRESS_376833] a stent will 
be made.  If a stent placement is not possible due to non -device related reasons (such as 
inability to cannulate the CBD or reach the papi[INVESTIGATOR_9387], extensive tumor growth at site of papi[INVESTIGATOR_9387], 
etc.),  interventional radiologic (IR) access is allowed and, where possible, should be 
associated with placement of a study stent over a transhepatically inserted guide -wire in a 
"rendez -vous" procedure.  Percutaneous trans hepatic cholangiograpy (PTC) and a subsequent 
internal drainage with a stent placement may be done at the same time (one -stage procedure), 
or PTC with external drainage  may be performed 2 -3 days before stent insertion (two -stage 
procedure) per standard of  practice.  If access to the biliary tree or endoscopic placement of 
the study stent through a â€œrendez -vousâ€ procedure fails and patient requires percutaneous 
transhepatic biliary drainage (PTBD), then the patient will exit the study.  
                                                                                                               Confidential  
20-Oct-[ADDRESS_376834] Protoc ol  
90914721 /Ver AD 
  Page [ADDRESS_376835] Protocol  
  90914721 /Ver AD 
  Page 20 of 44 
 
 Table 1.  Study Event Schedule  
 
Study Visit  Screening  Baseline / Stent 
Placement 
Procedure  Pre-Operative 
Visit  
Week 2â€  Biliary 
Reintervention  
(if applicable ) Curative 
Intent  Surgery  Transition to 
Palliative 
Treatment Visit  
(if applicable)  [ADDRESS_376836] -Op 
Follow up Visit  
(if applicable)  Long Term  
Follow up Visit  
120 Days*  
 
Window  N/A N/A Â±3 d N/A N/A N/A Â±7 d Â±14 d 
ICF X        
Eligibility Criteria 
Assessment  X        
Demographics   X       
Medical History   X       
Assessment of Biliary 
Obstructive Symptoms   X X  X X X X 
Laboratory  Tests   X X  X X X X 
Tumor Diagnosis, Staging 
& Characteristics   X       
Randomization   
X   
  
  
Stent Details   
X   X  
(if applicable)    
  
Procedure Details   
X   X  
(if applicable)    
  
Operative Details      X    
Specimen Pathology      X    
Stent Removal     X  
(if applicable)  X  
(if applicable)     
Adverse Event s X  (as applicable)  
Protocol Deviations  X  (as applicable)  
* Visit may occur up to [ADDRESS_376837] -randomization ;  â€  Visit may be conducted in the office or via telephone with liver function tests drawn and sent from local clinic/hospi[INVESTIGATOR_307].
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376838] Protocol  
90914721 /Ver AD 
  Page 21 of 44 
 7.2. Screening   
â€¢ Informed Consent  
â€¢ Eligibility Criteria Assessment   
No study -specific testing will be conducted until the subject has signed the study specific  
informed consent form ( ICF).  
Informed consent must be obtained for all subjects who are potential study candidates. 
Subjects will be asked to sign the ICF before any study -specific tests or procedures are 
performed. The ICF is study -specific and must be approved by [CONTACT_1636] (IRB)/Ethics Committee (EC) at each center. Study personnel should explain that even 
if a subject agrees to pa rticipate in the study and signs  the study specific  ICF, the screening 
process may demonstrate that the subject is not a suitable candidate for the study.  
7.3. Baseline  Visit  (Day 0)â€”Office Visit  
â€¢ Demographics  
â€¢ Medical History   
â€¢ Tumor Diagnosis , Staging and Characteristics  
o Diagnostic modality  
o Tumor stage  
o Location and size of mass  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever/Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests    
o Serum albumin level  
o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
o SGOT  (AST â€”optional)  and SGPT (ALT)  
o Normal R anges  
â€¢ Randomization into Group 1 or Group 2  
7.4. Stent Placement  Procedure  Visit  (Group 2  subjects only )â€”Office Visit (may 
occur during Baseline visit)  
â€¢ Stent Details  (including stent choice)  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376839] Protocol  
90914721 /Ver AD 
  Page 22 of 44 
 â€¢ Procedure  Details  (including sphincterotomy information)  
â€¢ Adverse Events  (AEs)  
7.5. Pre-Operative Visit  (Week 2  +/-  3 days )â€”Telephone or Office Visit  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever/Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests    
o Serum albumin level  
o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
o SGOT (AST â€”optional) and SGPT (ALT)  
â€¢ AEs 
7.6. Biliary Reintervention Visit (Group 1 or 2)  â€”as needed  
â€¢ Timing  
â€¢ Reason for Biliary Reintervention  
â€¢ Type of Biliary Reintervention (including SEMS placement or removal ) 
â€¢ Adverse Events (AEs)  
7.7. Curative Intent Surgeryâ€”Office Visit  (within [ADDRESS_376840] -randomization)  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever/Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests   
o Serum albumin level  
o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376841] Protocol  
90914721 /Ver AD 
  Page 23 of 44 
 o SGOT (AST â€”optional) and SGPT (ALT)  
â€¢ Operative details:  
o Exploration  
o Resection  (including SEMS removal)  
o Reconstruction  
â€¢ Blood Loss  
â€¢ Intra and Post-Operative Transfusion  
â€¢ Post-Operative Course  
â€¢ Specimen Pathology (including margin status)  per World Health Organization 
(WHO ) classification system  
â€¢ AEs 
7.8. Transition to Palliative Management Visit (if applicable) â€”Telephone or Office 
Visit  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever /Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests   
o Serum albumin level  
o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
o SGOT (AST â€”optional) and SGPT (ALT)  
â€¢ AEs 
7.9. Post-Operative Follow -up Visit ([ADDRESS_376842]-Surgery  +/- 7 days, if 
applicable )â€”Telephone or Office Visit  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever/Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests   
o Serum albumin level  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376843] Protocol  
90914721 /Ver AD 
  Page 24 of 44 
 o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
o SGOT (AST â€”optional) and SGPT (ALT)  
â€¢ AEs 
7.10. Long Term Follow -up Visit (120 days â€”[ADDRESS_376844] randomization  +/- 14 
days)â€”Telephone or Office Visit  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain  
o Fever/Chills  
o Jaundice  
o Itching  
o Dark urine  
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Tests   
o Serum albumin level  
o Alkaline phosphatase  
o Total Bilirubin  
o Gamma GT  
o SGOT (AST â€”optional) and SGPT (ALT)  
â€¢ AEs 
7.11. Study Completion  
Each subject will be followed for [ADDRESS_376845] remains unresponsive to 
communication after three documented attempts by [CONTACT_464].  
8. Statistical Considerations  
8.1. Hypothesi s 
Statistical testing will be performed to determine if the  rate of complications for the Pre-
Operative Biliary Drainage with SEMS  group is non -inferior to the No Pre -Operative Biliary 
Drainage group. The null hypothesis is that the complication rate is inferior in the Pre -
Operative Bi liary Drainage with SEMS versus the No Pre -Operative Biliary Drainage group:  
 
Ho: Ï€testâˆ’Ï€control  â‰¥âˆ†  (Inferior)  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376846] Protocol  
90914721 /Ver AD 
  Page 25 of 44 
  
Ha: Ï€testâˆ’Ï€control  <âˆ†  (Non -inferior)  
 
where Ï€test  and Ï€control  are the probabilities of having pre -operative, operative and peri -
operative co mplications in the Pre -Operative Biliary Drainage with SEMS arm and No Pre -
Operative Biliary Drainage arm respectively, and âˆ† is defined as the non -inferiority margin.  
8.2. Sample Size  
A literature search of preoperative biliary drainage with self -expanding me tal stents in 
patients with pancreatic or periampullary  cancer yielded [ADDRESS_376847]-
operative complications was done:  
â€¢ A rate of 24.2% [95% CI: 13.2%, 37.2%] was calculated using the [ADDRESS_376848] 9Â®. If the P value from the exact Farrington -Manning test is <0.05 then the Pre-
Operative Biliary Drainage with SEMS  group will be considered non -inferior to the No Pre -
Operative Biliary Drainage  group. The expected  probability of complications in the  Pre-
Operative Biliary Drainage with SEMS  arm and No Pre -Operative Biliary Drainage  arm is 
37.2%, which was taken from the upper limit of the 95% CI from the meta -analysis described 
above and from the  only available Level 1 study comparing no drainage to preoperative 
stenting in which the complication rate was reported to be 39% in the no drainage arm.9 The 
non-inferiority margin ( âˆ†) is 15%.  Given these assumptions and a one -sided 5% significance 
level, 2 x 132 = 264 subjects will provide 80% power to reject the null hypothesis, that the 
Pre-Operative Biliary Drainage with SEMS  group is inferior to the No Pre -Operative Biliary 
Drainage  group.  
To compensate for possible loss of subjects after enrollmen t and complete assessment of 
inclusion/exclusion criteria, an additional 10% of subjects will be enrolled, for a total of 2 x 
147 = [ADDRESS_376849] is considered â€œenrolledâ€ after signing the study -specific ICF.  Subjects who sign 
the ICF but subsequently do not meet one or more of the eligibility  criteria provided in 
Section  5.2 and Section 5.3  will be considered screen failures and excluded from the study.  
8.3.2.  Intent -to-Treat Cohort  
This cohort consists of those â€œen rolledâ€ subjects who meet all inclusion/exclusion criteria 
and are subsequently randomized.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376850] Protocol  
90914721 /Ver AD 
  Page 26 of 44 
 8.3.3.  Per-Protocol Cohort  
The per -protocol cohort is a subset of the ITT subjects who are treated per protocol after 
randomization (Group 1 no stent, and Group 2 receive d a study stent)  and no major protocol 
deviations (ICH E9 definitions) . 
8.4. Data Analyses  
All statistical analyses will be done using The SAS System software, version 8 or higher 
(Copyright Â© [ADDRESS_376851], Cary, North Carolina [ZIP_CODE], 
[LOCATION_003]. All rights reserved).  
The distribution of prognostic factors between patients  with and without data will be 
examined. Statistical models that account for censored data will be employed in appropriate 
circumstances, e.g. for time -to-event outcomes. Sensitivity analyses will be conducted to 
assess the impact of missing data  on the interpretation of the results , e.g. a tippi[INVESTIGATOR_30350].  
 
8.4.1.  Baseline Data  
Baseline data will be summarized.  Subject  demographics, clinical history, risk factors, LFTs, 
tumor diagnosis, and obstruction symptoms  will be summarized using descriptive statis tics 
(e.g., mean, standard deviation, n, minimum, maximum) for continuous variables and 
frequency statistics for discrete variables.  
  
8.4.2.  Post-Procedure Endpoints  
Post-procedure information will be collected at regularly scheduled follow -up examinations 
as detailed in the clinical study event schedule and will be summarized using descriptive 
statistics for continuous variables (e.g., mean, standard deviation, n, min imum, maximum) 
and frequency tables or proportions for discrete variables.  
8.4.3.  Subgroup Analyses  
The subgroup analyses will include tabulating  the primary endpoint and select secondary 
endpoints by [CONTACT_547].  
8.4.4.  Justification of Pooling  
The analyses will be presen ted using pooled data across institutions. An analysis of the 
poolability will be made using logistic regression for binary outcomes, analysis of covariance 
for continuous outcomes, or proportional hazards regression for time -to-event outcomes, to 
assess d ifferences between study institutions and to justify pooling data across institutions.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376852] Protocol  
90914721 /Ver AD 
  Page 27 of 44 
 8.4.5.  Multivariable Analyses  
Univariate and multivariate analyses will be performed to assess possible predictors of the 
primary endpoint. Possible predictors may include any but not limited to 
demographic/baseline data and medical history data. Factors from the univariate model with 
pâ‰¤0.20 will also be modeled multivariately using a stepwise procedure in a generalized linear  
model  or Cox Proportional Hazards model . The significance thresholds for entry and exit into 
the model will be set to p<0.10.  
8.4.6.  Changes to Planned Analyses  
Any chan ges to the planned statistical analyses made prior to performing the analyses  will be 
documented in a Statistical Analysis Plan approved prior to performing the analyses.  
9. Potential Risks and Benefits  
9.1. Anticipated Adverse Device Effects with U se of WallFlex  Biliary Stent  
As per the commercial DFU included with the study devices, the potential complications 
associated with the use of the WallFlex Biliary FC and UC Stent  may include, but are not 
limited to:   
â€¢ Pain 
â€¢ Bleeding  
â€¢ Fever  
â€¢ Nausea  
â€¢ Vomiting  
â€¢ Infection  
â€¢ Infla mmation  
â€¢ Recurrent obstructive jaundice  
â€¢ Stent occlusion  
â€¢ Tumor overgrowth around ends of stent  
â€¢ Tumor ingrowth through the stent  
â€¢ Mucosal hyperplasia  
â€¢ Cholangitis  
â€¢ Cholecystitis*  
â€¢ Pancreatitis  
â€¢ Bile duct or duodenum ulceration  
â€¢ Perforation of duodenum or bile duct 
â€¢ Stent migration  
â€¢ Death (other than that due to normal disease progression)  
â€¢ Stent misplacement  
â€¢ Perforation of the gallbladder due to the stent covering the cystic duct*  
â€¢ Stent fracture  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376853] Protocol  
90914721 /Ver AD 
  Page 28 of 44 
 â€¢ Hepatic abscess  
 
*Note: In a small clinical trial of this device, two  out of four (50%) subjects who had 
a stent placed across the cystic duct developed cholecystitis. One of these subjects 
suffered a perforated gallbladder due to the stent covering the cystic duct, requiring a 
drain to be placed.  
 
As per the commercial DFU  included with the study devices, potential complications 
associated with stent removal during an ERCP procedure include, but are not limited to:  
â€¢ Pain 
â€¢ Bleeding  
â€¢ Fever  
â€¢ Nausea  
â€¢ Vomiting  
â€¢ Infection  
â€¢ Inflammation  
â€¢ Recurrent obstructive jaundice  
â€¢ Mucosal hyperplasia  
â€¢ Cholangitis  
â€¢ Cholecystitis  
â€¢ Pancreatitis  
â€¢ Ulceration of duodenum or bile duct  
â€¢ Perforation of duodenum or bile duct  
â€¢ Death (other than that due to normal disease progression)  
â€¢ Impaction to the common bile duct wall  
9.2. Anticipated Adverse Events in Patients Without Pre -Operative Biliary Drainage  
â€¢ Severe jaundice  
â€¢ Cholangitis  
9.3. Anticipated Surgical Adverse  Events  
â€¢ Pancreaticojejunostomy leakage  
â€¢ Delayed gastric emptying   
â€¢ Biliary leakage  
â€¢ Gastro/ -duodenojejunostomy leakage  
â€¢ Intra-abdominal abscess formation  
â€¢ Wound infection  
â€¢ Portal Vein Thrombosis  
â€¢ Cholangitis    
â€¢ Hemorrhage   
â€¢ (Emergency) (re)laparotomy    
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376854] Protocol  
90914721 /Ver AD 
  Page 29 of 44 
 â€¢ Pneumonia  
â€¢ Myocardial infarction   
â€¢ Mortality   
9.4. Risk Minimization Actions  
Additional risks may exist. Risks can be minimized through compliance with this protocol, 
performing procedures in the appropriate hospi[INVESTIGATOR_84365], adherence to subject 
selection criteria, close monitoring of the subject's physiologic status during research 
procedures and/or follow -ups and b y promptly supplying BSC with all pertinent information 
required by [CONTACT_3181].   The latter may facilitate inter -center communications regarding 
serious AEs.  
9.5. Anticipated Benefits  
Subjects may not receive any benefit from participating in this study but this study may 
provide a future benefit to medical science and other patients.   To date there is no broadly 
accepted standard of practice pertaining to pre -operative drainage of patients as defined by 
[CONTACT_307968].  
9.6. Risk to Benefit Rationale  
Based on prior BSCâ€™s clinical studies and collected reports in literature to -date, the risk -to-
benefit ratio is within reason for fors eeable risks. However, literature reports do not always 
capture all side effects. Observation and fo llow up of subjects is required as outlined in the 
protocol.  
10. Safety Reporting  
10.1.  Definitions and Classification  
Adverse event definitions are provided in Table 10.1-1.  
Table 10.1-1: Adverse Ev ent Definitions  
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO [ADDRESS_376855] clinical signs (including abnormal lab 
findings) in subjects, users or other persons, whether or not 
related to the investigational medical device. This includes 
events related to:  
â€¢ The investigational medical device or comparator  
â€¢ The procedures involved (study -required)  
For users/other persons, this definition is restricted to events 
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376856] Protocol  
90914721 /Ver AD 
  Page 30 of 44 
 Table 10.1-1: Adverse Ev ent Definitions  
Term  Definition  
related to the invest igational device  
Adverse Device Effect 
(ADE)  
 
Ref: ISO [ZIP_CODE] -2011  Adverse event related to the use of an investigational medical 
device:  
â€¢ This includes adverse events resulting from insufficient or 
inadequate instructions for the use, deployment, implantation, 
installation or operation, or any malfunction of the 
investigational medical device.  
â€¢ This includes any event resulting from use error or from 
intentional misuse of the investigational medical device.  
Serious Adverse Event 
(SAE)  
 
Ref: ISO [ZIP_CODE] -2011  An adverse event that:  
â€¢ Led to death  
â€¢ Led to a serious deterioration in the health of the subject that 
either resulted in:  
o a life -threatening illness or injury, or  
o a permanent impairment of a body structure or a body 
function, or  
o in-patient hospi[INVESTIGATOR_13266] (of 
an existing hospi[INVESTIGATOR_059]), or  
o medical or surgical intervention to prevent life -threatening 
illness or injury or permanent impairment to a body 
structure or a body function  
â€¢ Led to fetal distress , fetal death, or a congenital abnormality 
or birth defect.  
Note : Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_760], without serious 
deterioration in health, is not considered a serious adverse 
event.  
Note : For SAE reporting requirements see the information 
below for SADE.  
Serious Adverse Device 
Effect (SADE)  
 
Ref: ISO [ADDRESS_376857] that has resulted in any of the 
consequences characteristic of a serious adverse event.  
Note : All SAEs that could have led to a SADE if suitable action 
had not been taken or if circumstances had been less fortunate 
shall be reported as required by [CONTACT_1036]/EC, national 
regulations, or the protocol. If applicable, see MEDDEV 2.7/3 
12/[ADDRESS_376858] Protocol  
90914721 /Ver AD 
  Page 31 of 44 
 Table 10.1-1: Adverse Ev ent Definitions  
Term  Definition  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 
12/[ADDRESS_376859] to its identity, quality, durability, reliability, safety or 
performance.  
Note : Device deficien cies include malfunctions, use errors, and 
inadequate labeling.  
Note : All device deficiencies that could have led to a SADE if 
suitable action had not been taken or if circumstances had been 
less fortunate shall be reported as required by [CONTACT_1036]/EC,  
national regulations, or the protocol. If applicable, see 
MEDDEV 2.7/3 12/2010 for reporting timeline requirements.  
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
 
Underlying diseases are not reported as AEs unless there is an increase in severity or 
frequency during the course of the investigation. Death should not be recorded as an AE, but 
should only be reflected as an outcome of a specific SAE (see Table 10.1-1 for AE 
definitions).  
Any AE experienced by [CONTACT_307969], whether during or 
subsequent to the procedure, must be recorded in the eCRF.  
Refer to Section 9 for the known risks associated with the study device(s).  
Adverse e vents that occur during the course of the study will be evaluated against a list of 
pre-specified complication criteria as defined in Section 12.14.  Determination of whether an 
AE meets the definition of a pre-specified complication wi ll be made by [CONTACT_67926].  
10.2. Relationship to Study Device(s)  
The Investigator must assess the relationship of the AE to the study device as related or 
unrelated. See criteria in Table 10.2-2:  
Table 10.2-2: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
Unrelated  The adverse event is determined to be due to a concurrent illness or 
effect of another device/drug and is not related to the investigational 
product.  
Related  â€¢ The adverse event is determined to be potentially related to the 
investigational product, and an alternative etiology is equally or less 
likely compared to the potential relationship to investigational 
product.  
â€¢ There is a strong relationship to investigational product, or recurs on 
re-challenge, and another etiology is unlikely.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376860] Protocol  
90914721 /Ver AD 
  Page 32 of 44 
 Table 10.2-2: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
â€¢ There is no other reasonable medical explanation for the event.  
10.3.  Investigator Reporting Requirements  
Investigators will be required to report all SAEs and ADEs.  
10.3.1.   Serious Adverse Events   
These events should be reported to the Global Safety Office and/or Project Manager within [ADDRESS_376861] becoming aware of the event.  Events should be documented in the 
eCRF and all relevant source documentation for the event should be provided t o the Global 
Safety Office, as applicable.  
10.3.2.   Adverse Events  
Device -related events should be reported to the Global Safety Office and/or Project Manager 
within [ADDRESS_376862] Manager and/or Global Safety Office within [ADDRESS_376863] becoming aware of the event.  Events should be documented in the 
eCRF.  
10.4.  [LOCATION_011] Scientific De vice Deficiencies  
All device deficiencies (including but not limited to failures, malfunctions, use errors, 
product nonconformities, and labeling errors) will be documented and reported to BSC. If 
possible, the device(s) should be returned to BSC for analysis. Instructions for returning the 
investigational device(s) will be provided. If it is not possible to return the device, the 
investigator should document why the device was not returned and the final disposition of the 
device.  
Device deficiencies, failures, malfunctions , and product nonconformities are not to be 
reported as adverse events. However, if there is an adverse event that results from a device 
failure or malfunction, that specific event would be recorded on the appropriate eCRF.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376864] Protocol  
90914721 /Ver AD 
  Page 33 of 44 
 10.5.  Reporting to Regulatory Authori ties / IRBs / ECs / Investigators  
BSC is responsible for reporting adverse event information to all participating investigators 
and regulatory authorities, as applicable.  
The Principal Investigator [INVESTIGATOR_307957]/EC  and regulatory au thorities 
of SAE s as required by [CONTACT_307970].   
11. Bibliography  
1. Decker C, Christein JD, Phadnis MA, Wilcox CM, Varadarajulu S. Biliary metal 
stents are superior to plastic stents for preoperative  biliary decompression in 
pancreatic cancer.  Surg Endosc. 2011 Jul;25(7):2364 -7. Epub 2011 Mar 4.  
2. Wasan SM, Ross WA, Staerkel GA, Lee GH.  Use of Expandable Metallic Biliary 
Stents in Resectable Pancreatic Cancer. Am J Gastroenterol. 2005;100:2056 â€“2061.  
3. Mullen JT, Lee JH, Gomez HF, Ross WA, et al.  Pancreaticoduodenectomy After 
Placement of Endobiliary Metal Stents.  J Gastrointest Surg 2005;9:1094 â€“1105.  
4. Sanders MK, El Hajj II, Slivka A, et al  Placement of Self -Expanding Metal Biliary 
Stents (SEMS) in Patients with Resectable Pancreatic Cancer [Abstract].  Gastrointest 
Endosc 2009; 69(5)  
5. Kahaleh M, Brock A, Conaway MR, et al. Covered selfâˆ’expandable meta l stents in 
pancreatic malignancy regardless of resectability: a new concept validated by a 
decision analysis.  Endoscopy 2007 Apr;39(4):319 -24 
6. Pop GH, Richter JA, Sauer B, et al. Bridge to surgery using partially covered self -
expandable metal stents (PCMS ) in malignant biliary stricture: an acceptable 
paradigm?  Surg Endosc 2011 Feb;25(2):613 -8 
7. Lawrence C , Howell DA, Conklin DE, et al. Delayed pancreaticoduodenectomy for 
cancer patients with prior ERCP -placed, nonforeshortening, self -expanding metal 
stent s: a positive outcome, Gastrointest Endosc 2006 May;63 (6): 804 -807 
8. Singal AK, Ross WA, Guturu P, et al.  Self -Expanding Metal Stents for Biliary 
Drainage in Patients with Resectable Pancreatic Cancer: Single -Center Experience 
with 79 Cases.  Dig Dis Sci 2 011 Jul 13. [Epub ahead of print]  
9. van der Gaag NA, Rauws EAJ, van Eijck CHJ, et al. Preoperative Biliary Drainage 
for Cancer of the Head of the Pancreas.  N Engl J Med 2010;362:129 -37. 
10. Hariharan D, Saied A, Kocher HM.  Analysis of mortality rates for pancr eatic cancer 
across the world. HPB (Oxford). 2008; 10(1): 58 â€“62.  
11. American Cancer Society.  Cancer Facts and Figures 2012. Atlanta : American Cancer 
Society;  2012.  
12. NCCN Clinical Guidelines in Oncology Pancreatic Adenocarcinoma Version 2.2011, 
NCCN.org  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376865] Protocol  
90914721 /Ver AD 
  Page 34 of 44 
 13. Caller y MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan 
DC. Pretreatment assessment of resectable and borderline resectable pancreatic 
cancer: expert consensus statement.  Ann Surg On col. 2009 Jul;16(7):1727 -33. Epub 
2009 Apr 24.  
14. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by [CONTACT_20521].  Clin 
Gastroenterol Hepatol. 2008 Dec;6(12):[ADDRESS_376866] 
Surg. 2004 Mar -Apr;8(3):[ADDRESS_376867]. Surgical  and pathologic correlation.  
JOP. 2007 Nov 9;8(6):753 -8. 
17. Schima W, Ba -Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C. State -of-the-
art magnetic resonance imaging of pancreatic cancer.  Top Magn Reson Imaging. 
2007 Dec;18(6):421 -9. Review.  
18. NCCN Clinical Guidelines in Oncology Pancreatic Adenocarcinoma Version 2.2012, 
NCCN.org  
19. RÃ¶sch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, Classen M. 
Staging of pancreatic and ampullary carcinoma by [CONTACT_307971]. 
Comparison with conventional sonography, computed tomography, and angiography.  
Gastroenterology. 1992 Jan;102(1):188 -99. 
20. Varadarajulu S, Wallace MB.  Applications of endoscopic ultrasonography in 
pancreatic cancer.  Cancer Control. 2004 Jan -Feb;11(1):[ADDRESS_376868];16(5):458 -63. 
22. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and 
assessment of resectability of pancreatic cancer.  Arch Surg. 1990 Feb;125(2):230 -3. 
23. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor -node -metastasis staging of 
pancreatic  adenocarcinoma.  CA Cancer J Clin. 2008 Mar -Apr;58(2):[ADDRESS_376869], Compton CC, et al., eds. Exocrine and endocrine pancreas.  
AJCC Cancer Staging Manual. 7th ed. [LOCATION_001], NY: Springer, 2010, pp [ADDRESS_376870] Res Clin Gastroenterol.  2006;20(2):349 â€“364. 
26. Bonin EA, Baron TH. Preoperative  biliary  stents  in pancreatic  cancer.  J Hepatobiliary 
Pancreat Sci. 2011 Sep;18(5):[ADDRESS_376871] Protocol  
90914721 /Ver AD 
  Page 35 of 44 
 27. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004; 363 
(9414):1049 -1057.  
28. Gumbs AA, Rodriguez Rivera AM, Milone L, Hoffman JP. Laparoscopic 
pancreatoduodenectomy: a review of 285 published cases.  Ann Surg Oncol. 2011 
May;18(5):1335 -41. Epub 2011 Jan 5. Review.  
29. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605 â€“1617.  
30. Boulay BR, Gardner TB, Gordon SR.  Occlusion rate and complications of plastic 
biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for 
pancreatic cancer with malignant biliary obstruction.  J Clin Gastroenterol 2010 
Jul;44(6):452 -5. 
31. Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a 
systematic review and meta -analysis of endoscopi c and surgical by[CONTACT_307972].  
Cancer Treat Rev. 2007 Apr;33(2):213 -21. Epub 2006 Dec 8. Review.  
12. Appendices :  Sponsor Required Protocol Sections  
12.1. Data Management  
12.1.1.   Data Collection, Processing, and Review  
Subject data will be recorded  in a limited access  secure electronic data capture (EDC) 
system.   
The clinical database will reside on a production server. All changes made to the clinical data 
will be captured in an electronic audit trail and available for review by [CONTACT_307973] ( BSC ) or its representative. The associated software and database have been 
designed to meet regulatory compliance for deployment as part of a validated system 
compliant with laws and regulations applicable to the conduct of clinical studies  pertaining to 
the use of electronic records and signatures. Database b ackups are performed regularly.  
The Investigator provide s his/her electronic signature [CONTACT_307985] (eCRFs) in compliance with local regulations. A written signature [CONTACT_307986] [CONTACT_1295]. Changes to data 
previously submitted to the sponsor require a new electronic signature [CONTACT_3265] [CONTACT_307974].  
Visual and/or electronic data review will be performed to identify possible data 
discrepancies. Manual and/or automatic queries will be created in the EDC system and will 
be issued to the site for appropriate response. Site staff will be responsible for resolving all 
queries in the database.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376872] Protocol  
90914721 /Ver AD 
  Page 36 of 44 
 12.1.2.   Data Retention  
The Investigator will maintai n, at the investigative site,  in original format all essential study  
documents and source documentation that support the data collected on the study subjects in 
compliance with ICH/GCP guidelines.  Documents must be retained for at least [ADDRESS_376873]. These documents will be 
retained for a longer period of time by [CONTACT_307975] . It is BSCâ€™s responsibility to inform the Investigator when these documents no 
longer need to be maintained. The Investigator will take measures to ensure that these 
essential documents are not accidentally damaged or destro yed. If for any reason the 
Investigator withdraws responsibility for maintaining these essential documents, custody 
must be transferred to an individual who will assume responsibility and BSC must receive 
written notification of this custodial change.  
12.2.  Amendments   
If a protocol revision  is necessary which affect s the rights, safety or welfare of the subject or 
scientific integrity of the data , an amendment is required. Appropriate approvals (e.g., 
IRB/EC/ FDA/CA)  of the  revised protocol must be obtained prior to implementation.  
12.3.  Deviation s 
An Investigator must not make any changes or deviate from this protocol, except to protect 
the life and physical well -being of a subject in an emergency. An investigator shall notify the 
sponsor and the  reviewing IRB/E C of any deviation from the investigational plan to protect 
the life or physical well-being  of a subject  in an emergency , and those deviations which 
affect the scientific integrity of the clinical investigation . Such notice shall be given a s soon 
as possible, but no later than [ADDRESS_376874] be documented and reported to the sponsor  using the Protocol Deviation 
EDC CRF.  Sites may also be required to report deviations to the IRB/ EC, per local 
guidelines and government regulations.  
Deviations will be reviewed and evaluated on an ongoing basis and, as necessary, appropriate 
corrective and preventive actions (including notification, center re -training, or 
discontinuation)  will be put into place by [CONTACT_456].  
12.4.  Device /Equipment  Account ability  
There are no investigational devices used in this study. The WallFlex Biliary Fully Covered 
and Uncovered Stent Systems are available for commercial use in the geographic areas in 
which this clinical study is taking place; therefore, there is no re quirement for device 
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376875] Protocol  
90914721 /Ver AD 
  Page [ADDRESS_376876]â€™s medical record and recorded on the appropriate case report form.  
Any individual country/region requirements that depart from the  aforementioned will be 
implemented on a case -by-case basis.  
12.5.  Compliance  
12.5.1.   Statement of Compliance  
This study will be conducted in accordance with relevant sections of the International 
Standard (ISO) [ZIP_CODE]: Clinical Investigation of Medical devices for Hum an Subjects â€“ Good 
Clinical Practice, the relevant parts of the ICH Guidelines for Good Clinical Practices, ethical 
principles that have their origins in the Declaration of Helsinki, and pertinent individual 
country laws and regulations. The study will not  begin until the required approval/favorable 
opi[INVESTIGATOR_44636]/or regulatory authority has been obtained, if appropriate. Any 
additional requirements imposed by [CONTACT_271467],                     
if appropriate.  
12.5.2.   Investigator Responsibilities  
The Principal  Investigator  [INVESTIGATOR_307958], the investigational 
plan/protocol , ISO [ZIP_CODE], ethical principles th at have their origins in the  Declaration of 
Helsinki,  any conditions of approval imposed by [CONTACT_3488]/EC , and prevailing local 
and/or country laws and/or regulations , whichever affords the greater protection to the 
subject . 
The Principal Investigatorâ€™s responsibilities include, but are not limited to, the  following.   
â€¢ Prior to beginning the study, sign the Investigator Agreement and Protocol Signature 
[CONTACT_71660]/her agreement to conduct the study in accordance with the 
protocol . 
â€¢ Provide his/her qualifications and experience to assume responsibility for the proper 
conduct of the study and that of key members of the center team through up -to-date 
curriculum vitae or other relevant documentation and disclose potential conflicts of 
interest, including financial, that may interfere with the conduct of the clinical study or 
interpretation of results . 
â€¢ Make no changes in or deviate from this protocol, except to protect the life and physical 
well-being of a subject in an emergency ; document and explain any deviation from the 
approved protocol that occurred during the course of the clinical  investigation . 
â€¢ Create and maintain source documents throughout the clinical study and ensure their 
availability with direct access during monitoring visits  or audits; ensure that all clinical -
investigation -related records are retained per requirements . 
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376877] Protocol  
90914721 /Ver AD 
  Page 38 of 44 
 â€¢ Ensure the accuracy, completeness, legibility, and timeliness of the data reported to the 
sponsor in the CRFs and in all required reports . 
â€¢ Record , report, and assess (seriousness and relationship to the device/procedure) every 
adverse event and observed device deficiency . 
â€¢ Report to BSC , per the protocol requirements, all SAEs and device deficiencies that 
could have led to a SADE.  
â€¢ Report to the IRB/EC and regula tory authorities any SAEs and device deficiencies that 
could have led to a SADE, if required by [CONTACT_272611]/ EC, and supply BSC with any additional requested information related to the 
safety reporting of a partic ular event . 
â€¢ Maintain the device accountability records and control of the device , ensuring that the 
investigational device is used only b y authorized/designated users and in accordance with 
this protocol and instructions/directions for use.  
â€¢ Allow the sponsor to perform monitoring and auditing activities, and be accessible to the 
monitor and respond to questions during monitoring visits . 
â€¢ Allow and support regulatory authorities and the IRB/ EC when performing auditing 
activities . 
â€¢ Ensure that informed con sent is obtained in accordance with this protocol and local 
IRB/EC requirements . 
â€¢ Provide adequate medical care to a subject during and after a subjectâ€™s participation in a 
clinical study in the case of adverse events, as described in the Informed Consent Form 
(ICF). 
â€¢ Inform the subject of the nature and possible cause of any adverse events experienced . 
â€¢ As applicable, provide the subject with necessary instructions on proper use, handling, 
storage , and return of the investigational device when it is used/operated by [CONTACT_423] . 
â€¢ Inform the subject of any new significant findings occurring during the clinical 
investigation, including the need for additional medical care that may be required . 
â€¢ Provide the subject with well -defined procedures for possible emergency situations 
related to the clinical study , and make the necessary arrangements for emergency 
treatment, including decoding procedures for blinded/masked clinical investigations, as 
neede d. 
â€¢ Ensure that clinical medical records are clearly marked to indicate that the subject is 
enrolled in this clinical study . 
â€¢ Ensure that, i f appropriate, subjects enrolled in the clinical investigation are provided 
with some means of showing their participa tion in the clinical investigation, together with 
identification and compliance information for concomitant treatment measures (contact 
[CONTACT_5735]) . 
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376878] Protocol  
90914721 /Ver AD 
  Page 39 of 44 
 â€¢ Inform , with the subjectâ€™s approval or when required by [CONTACT_307976], the 
subjectâ€™s personal physician about the subjectâ€™s participation in the clinical investigation . 
â€¢ Make all reasonable efforts to ascertain the reason(s) for a subjectâ€™s premature 
withdrawal from clinical investigation while fully respecting the sub jectâ€™s rights.  
â€¢ Ensure that an adequate investigation site team and facilities exist and are maintained and 
documented  during the clinical investigation . 
â€¢ Ensure that maintenance and calibration of the equipment relevant for the assessment of 
the clinical  investigation is appropriately performed a nd documented, where applicable . 
12.5.3.   Delegation of Responsibility  
When specific tasks are delegated by [CONTACT_2413] , included but not limited to conduct ing 
the informed consent process , the investigator is responsible for providing appropriate 
training and adequate supervision of those to whom tasks are delegated. The investigator is 
accountable for regulatory violations resulting from failure to adequately supervise the 
conduct of the clinical study.  
12.6.  Institutional Review Board/ Ethics Committee  
Prior to gaining Approval -to-Enroll status, t he investigational center will provide to the 
sponsor documentation verifying that their IRB/EC is registered or that registration has been 
submitte d to the appropriate agency, as applicable according to national/regulatory 
requirement s.   
A copy of the written IRB/ EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form , must be received by  [CONTACT_307977] /equipment . Prior approval must also be obtained for other materials related to subject 
recruitment or which will be provided to the subject . 
Annual IRB/ EC approval and renewal s will be obtained  throughout the duration of the study 
as required by [CONTACT_5737]/country or  IRB/EC  requirements . Copi[INVESTIGATOR_5699]â€™s reports 
and the IRB/EC continuance of approval must be provided to the sponsor .  
12.7.  Sponsor Responsibilities  
All information and data sent to BSC  concerning subjects  or their participation in this study 
will be considered confidential by [CONTACT_71640] . Only authorized BSC  personnel or a BSC  
representative will have access to these confidential records . Aut horized regulatory personnel 
have the right to inspect and copy all records pertinent to this study . Study data collected 
during this study may be used by [CONTACT_307978] , publication, and to 
support future research and/or other business  purposes. All data used in the analysis and 
reporting of this study will be without identifiable reference to specific subject  name.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376879] Protocol  
90914721 /Ver AD 
  Page 40 of 44 
 [LOCATION_011] Scientific will keep subjects â€™ health information confidential in accordance with all 
applicable laws and regulatio ns.  [LOCATION_011] Scientific may use subjects â€™ health information to 
conduct this research, as well as for additional purposes, such as overseeing and improving 
the performance of its device, new medical research and proposals for developi[INVESTIGATOR_307959], and other business purposes. Information received during 
the study will not be used to market to subjects ; subject  names will not be placed on any 
mailing lists or sold to anyone for marketing purposes.  
12.8.  Insurance  
Where required by [CONTACT_5737]/ country regulation, proof and type of insurance coverage , by [CONTACT_307979].  
12.9.  Monitoring  
Monitoring will be performed during the study to assess continued compliance with the 
protocol and applicable regulations. In addition, the monitor verifies that study records are 
adequately maintained, that data are reported in a satisfactory manner with respect to 
timeliness, adequacy, and accuracy and that the Investigator continues to have sufficient staff 
and facilities to c onduct the study safely and effectively. The Investigator/institution 
guarantees direct access to original source documents by [CONTACT_5724], their designees and 
appropriate regulatory authorities.  
The study may also be subject to a quality assurance audit  by [CONTACT_5742], as well as 
inspection by [CONTACT_4708]. It is important that the Investigator and 
relevant study personnel are available during on -site monitoring visits or audits and that 
sufficient time is devoted to the pr ocess.  
12.10.  Informed Consent  
Subject  participation in this clinical study is voluntary.  Informed Consent is required from 
all subjects  or their legally authorized representative. The Investigator is responsible for 
ensuring that Informed Consent is obtained pr ior to the use of any investigational devices, 
study -required procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in accordance with the 
principles of the Declaration of Helsinki, ISO [ZIP_CODE], any applicable national regulations, and 
local Ethics Committee and/or Regulatory  authority  body, as applicable. The ICF must be 
approved by [CONTACT_16018]â€™s IRB/ EC, or central IRB, if applicable.  
[LOCATION_011] Scientific will provide a study -specific template of the ICF  to investigators 
participating in this study. The ICF template may be modified to meet the requirements of the 
investigative centerâ€™s IRB/EC.  Any modification requires approval from BSC  prior to use of 
the form.  The ICF must be in a language understanda ble to the subject and if needed, BSC 
will assist the center in obtaining a written consent translation. Translated consent forms 
must also have IRB/EC approval prior to their use.  Privacy  language shall be included in the 
body of the form or as a separat e form  as applicable .   
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376880] Protocol  
90914721 /Ver AD 
  Page 41 of 44 
 The process of obtaining Informed Consent shall:  
â€¢ be conducted by [CONTACT_54421] I nvestigator or designee authorized to conduct the process ,  
â€¢ include a description of all aspects of the clinical study that are relevant to the subject â€™s 
decision to participate throughout the clinical study,  
â€¢ avoid any coercion of or undue influence of subjects  to participate,  
â€¢ not waive or appear to waive subject â€™s legal rights,  
â€¢ use native language that is non -technical and understandable to the subject  or his/her 
legal representative,  
â€¢ provide ample time for the subject  to consider participation and ask questions if 
necessary,  
â€¢ ensure important new information is provided to new and existing subjects  throughout the 
clinical study . 
The ICF shall always be si gned and personally dated by [CONTACT_307980]. If a legal representative signs, the subject shall be asked to provide informed 
consent for continued participation as soon as his/her medical condition allows. The original 
signed ICF will be retained by [CONTACT_71657] a copy of the signed and dated document  and 
any other written information  must be given to the person signing the form.  
Failure to obtain subject  consent will be reported by [CONTACT_307981] (e.g. , FDA requirement is within 5 working days of learning 
of such an event). Any violations of the informed consent process must be reported as 
deviations  to the sponsor and local regulatory authorities (e.g. IRB/EC) , as appropriate . 
If new information becomes available that can significantly affect a subject 's future health 
and medical care , that information shall be provided to the affected subject (s) in written form 
via a revised ICF or , in some situations, enrolled subjects  may be requested to sign and date 
an addendum to the ICF. In addition to new significant information during the cours e of a 
study, other situations may necessitate revision of the ICF, such as if there are amendments 
to the protocol, a change in P rincipal Investigator , administrative changes, or following 
annual review by [CONTACT_1201]/EC. The new version of the ICF must be ap proved by [CONTACT_1201]/EC. 
[LOCATION_011] Scientific approval is required if changes to the revised ICF are requested by [CONTACT_282085]â€™s IRB/EC. The IRB/EC will determine the subject  population to be re -consented.  
12.11.  Committ ees 
12.11.1.    Safety Monitoring Process   
An independent  data rev iew (IDR) board comprised of  physician experts in surgery and 
gastroenterological endoscopy  not participating in the clinical study and with no affiliation 
with BSC , will provide external oversight and review for potential safety concerns.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376881] Protocol  
90914721 /Ver AD 
  Page [ADDRESS_376882] safety or issues relating to data monitoring or quality control will be 
submitted in writing to BSC for consideration.  
12.12.  Suspension or Termination  
12.12.1.    Prem ature Termination of the Study  
[LOCATION_011] Scientific Corporation reserves the right to terminate the study at any stage but 
intends to exercise this right only for valid scientific or administrative reasons and reasons 
related to protection of subjects.  Investigators, associated IRBs/ECs, and regulatory 
authorities, as applicable, will be notified in writing in the event of study termination.  
12.12.2.    Criteria for Premature Termination of the Study  
Possible reasons for premature study termination incl ude, but are not limited to, the 
following.  
â€¢ The occurrence of unanticipated adverse device effects that present a significant or 
unreasonable risk to subjects enrolled in the study.  
â€¢ An enrollment rate far below expectation that prejudices the conclusion of  the study.  
â€¢ A decision on the part of [LOCATION_011] Scientific to suspend or discontinue development of the 
device.  
12.12.3.    Termination of Study Participation  by [CONTACT_5717]/ 
EC Approval  
Any investigator, or IRB/ EC in the Preoperative Biliar y Drainage RCT  Study may 
discontinue participation in the study or withdrawal approval of the study, respectively, with 
suitable written notice to [LOCATION_011] Scientific. Investigators, associated IRBs/ECs, and 
regulatory authorities, as applicable, will be not ified in writing in the event of these 
occurrences.  
12.12.4.    Requirements for Documentation and Subject Follow -up 
In the event of premature study termination a written statement as to why the premature 
termination has occurred will be provided to all participatin g centers by [CONTACT_5756]. 
The IRB/EC and regulatory authorities, as applicable, will be notified. Detailed information 
on how enrolled subjects will be managed thereafter will be provided.  
In the event an IRB or EC terminates participation in the st udy, participating investigators, 
associated IRBs/ECs, and regulatory authorities, as applicable, will be notified in writing. 
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376883] Protocol  
90914721 /Ver AD 
  Page 43 of 44 
 Detailed information on how enrolled subjects will be managed thereafter will be provided 
by [CONTACT_5756].  
In the event an i nvestigator terminates participation in the study, study responsibility will be 
transferred to a co -investigator, if possible. In the event there are no opportunities to transfer 
investigator responsibility; detailed information on how enrolled subjects wi ll be managed 
thereafter will be provided by [CONTACT_5756].  
The investigator must return all documents and investigational product to [LOCATION_011] Scientific, 
unless this action would jeopardize the rights, safety, or welfare of the subjects.  
12.12.5.    Criteria for Suspending/Terminating a Study Center  
[LOCATION_011] Scientific Corporation  reserves the right to stop the inclusion of subjects at a study 
center at any time after the study initiation visit if no subjects have been enrolled for a period 
beyond  2 months after cen ter initiation, or if the center has multiple or  severe protocol 
violations/nonc ompliance without justification and/or fails to follow remedial actions.  
In the event of termination of investigator participation, all study devices and testing 
equipment , as applicable,  will be returned to BSC  unless this action would jeopardize the 
rights, safety or well -being of the subjects . The IRB/EC and regulatory authorities, as 
applicable, should be notified. All subjects  enrolled in the study  at the center will continue to 
be followed per protocol.  The Principal Investigator [INVESTIGATOR_307960] -up visits unless BSC  notifies the investigational center otherwise . 
12.13.  Publication Policy  
In accordance with the Corporate Policy on the Conduct of Human Subject Research, BSC 
requires disclosure of its involvement as a sponsor or financial supporter in any publication 
or presentation relating to a BSC study or its results. In accordance with the Corporate Policy 
for the Condu ct of Human Subject Research, BSC will submit study results for publication 
(regardless of study outcome) following the conclusion or termination of the study. [LOCATION_011] 
Scientific Corporation adheres to the Contributorship Criteria set forth in the Uniform 
Requirements of the International Committee of Medical Journal Editors (ICMJE; 
http://www.icmje.org). In order to ensure the public disclosure of study results in a timely 
manner, while maintaining an unbiased presentation of study outcomes, BSC personnel m ay 
assist authors and investigators in publication preparation provided the following guidelines 
are followed.  
â€¢ All authorship and contributorship requirements as described above must be followed.  
â€¢ BSC involvement in the publication preparation and the BSC P ublication Policy should 
be discussed with the Coordinating Principal Investigator(s) and/or Executive/ Steering 
Committee at the onset of the project.  
â€¢ The First and Senior authors are the primary drivers of decisions regarding publication 
content, review, approval, and submission.  
                                                                                                                 Confidential  
20-Oct-[ADDRESS_376884] Protocol  
90914721 /Ver AD 
  Page 44 of 44 
 12.14.  Definitions  of complication criteria (per van der Gaag article) : 
Specific PBD (ERCP, PTC) related : 
o Acute pancreatitis   Abdominal pain and a serum concentration of pancreatic 
enzymes (amylase or lipase) three or  more times the upper limit of normal, that 
required more than one night of hospi[INVESTIGATOR_059]  
o Acute cholecystitis   No suggestive clinical or radiographic signs of acute 
cholecystitis before the procedure and if  emergency cholecystectomy is subsequently 
required  
o Perforation   Retroperitoneal or bowel -wall perforation documented by [CONTACT_307982]  
o Stent Occlusion  Recurring obstructive jaundice with necessary stent replacement  
Specific surgery related : 
o Pancreaticojejunostomy leaka ge Drain output of any measurable volume of fluid on 
or after postoperative day 3 with an  amylase content greater than 3 times the serum 
amylase activity, graded according to clinical  course (ISGPS grade A, B, C), or direct 
visual evidence of defect at ana stomosis  
o Delayed gastric emptying   Gastric stasis requiring nasogastric intubation for 10 days 
or more, or the inability to tolerate a  regular (solid) diet on or before the fourteenth 
postoperative day, not due to sequelae of  intra-abdominal complications (i.e. abscess, 
anastomotic leakage)  
o Biliary leakage  Bilirubin in abdominal drain or dehiscence found at laparotomy  
o Gastro /-duodenojejunostomy leakage  Conclusive radiographic or direct visual 
evidence of a defect of the anastomosis  
o Intra -abdominal abscess  formation  Intra -abdominal fluid collection with positive 
cultures identified by [CONTACT_307983], associated with 
persistent fever and elevations of white blood cells  
o Wound infection  Requiring intervention otherwise considered as minor  complication  
o Portal Vein Thrombosis  Conclusive radiologic evidence of thrombosis  
Following either procedure : 
o Cholangitis   Elevation in temperature more than 38Â°C, thought to have a biliary 
cause, without  concomitant evidence of acute cholecystitis, requir ing intervention  
o Hemorrhage  Bleeding after the index procedure requiring transfusion of â‰¥4 units of 
packed cells within a  24-hour period, or leading to relaparotomy/intervention  
o (Emergency) (re)laparotomy   Any (other) reason following either preoperative 
biliary drainage or another surgical procedure  
o Pneumonia  Pulmonary infection with radiological confirmation and requiring 
antibiotic treatment  
o Mortality  In-hospi[INVESTIGATOR_39473], due to protocol complications or any cause, including 
progression of  disease, within the study period  